BioTech / Biotech / Pharmaceuticals / Pharmaceutical / Vaccine / Drug / Drugs / Vaccines / Medicine / Therapeutics / RNAi / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Accelerator / aflibercept / allergy / Alnylam Pharma ceuticals / amazon / Amicus Therapeutics / apple / Approval / Biogen / cancer / clinical trials / cost / CVS / CVS Caremark / CVS Health / drug price / EpiPen / Express Scripts / Eylea / Fabry Disease / fasinumab / FDA / FDA approval / Gene Therapy / generic / google / guidance / hereditary transthyretin amyloidosis / HIV / ICER / Institute for Clinical Economic Review / interference / Kaiser Health News / Life Sciences / Macular Degeneration / Magnolia Neurosciences / Microsoft / migalastat / National Institute for Health and Care Excellence / nusinersen / Oncology / opidoids / Orchard Therapeutics / Prices / Pricing / rejection / RNA interfernece / RNAi medicine / Safety / Spinraza / Teva Pharmaceutical / therapeies / Trump administration / VC / Venture Capital / ViiV Healthcare

Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More

Posted on: Aug 17, 2018 | Posted by: Biotech Mag

We'll start the roundup this week with two drug approvals that came late last Friday. Both were landmarks for the companies receiving the nod, Alnylam Pharmaceuticals and...